Items where Author is "Zhang, Yichen"

Article

Zhang, Yichen, Li, Huangqianyu, Chen, Jinyu, Naci, Huseyin ORCID: 0000-0002-7192-5751, Wagner, Anita K, Shi, Luwen and Guan, Xiaodong (2025) Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005–2022: an observational study. BMJ Evidence-Based Medicine. ISSN 2515-446X

Zhang, Yichen, Chen, Dingyi, Fu, Mengyuan, Shi, Luwen, Naci, Huseyin ORCID: 0000-0002-7192-5751, Wagner, Anita K., Ross, Joseph S. and Guan, Xiaodong (2025) Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. The Lancet Oncology, 26 (9). 1252 - 1260. ISSN 1470-2045

Zhang, Yichen, Chen, Dingyi, Fu, Mengyuan, Shi, Luwen, Naci, Huseyin ORCID: 0000-0002-7192-5751, Wagner, Anita Katharina, Ross, Joseph S. and Guan, Xiaodong (2025) Strength of evidence supporting cancer drug approvals in China, 2017-2021. Journal of Clinical Oncology, 43 (16_suppl). ISSN 0732-183X

Naci, Huseyin ORCID: 0000-0002-7192-5751, Zhang, Yichen, Woloshin, Steven, Guan, Xiaodong, Xu, Ziyue and Wagner, Anita K. (2024) Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. The Lancet Oncology, 25 (6). 760 - 769. ISSN 1470-2045

Wei, Yuxuan, Zhang, Yichen, Xu, Ziyue, Wang, Guoan, Zhou, Yue, Li, Huangqianyu, Shi, Luwen, Naci, Huseyin ORCID: 0000-0002-7192-5751, Wagner, Anita K. and Guan, Xiaodong (2024) Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020. The Lancet Regional Health - Western Pacific, 45. ISSN 2666-6065

Zhang, Yichen, Naci, Huseyin ORCID: 0000-0002-7192-5751, Wagner, Anita K., Xu, Ziyue, Yang, Yu, Zhu, Jun, Ji, Jiafu, Shi, Luwen and Guan, Xiaodong (2022) Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA network open, 5 (8). ISSN 2574-3805